NOVEL PYRROLO[1,2-d][1,2,4]TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS
The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, e...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
23.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The application is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.
La présente demande concerne des composés de formule (I), P, Q, A, B, m, n, R1, R2 et R3 étant définis selon la formule (I), en tant qu'effecteurs allostériques négatifs du récepteur métabotropique du glutamate du sous-type 7 (mGluR7), et qui sont utiles pour le traitement ou la prévention des troubles neurologiques, auditifs et psychiatriques associés à un dysfonctionnement du glutamate et des maladies dans lesquelles les récepteurs métabotropiques mGluR7 interviennent. La demande concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés de préparation de tels composés et de telles compositions, et l'utilisation de tels composés pour la prévention ou le traitement de troubles et de maladies neurologiques, auditifs et psychiatriques dans lesquels le mGluR7 intervient. |
---|---|
Bibliography: | Application Number: WO2023EP81726 |